Poseida Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark J. Gergen
- Full Time Employees
- 350
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9390 Towne Centre Drive San Diego CA United States of America 92121
- IPO Date
- Jul 10, 2020
- CIK
- 0001661460
- Website
- poseida.com
- Similar Companies
- Business
- Poseida Therapeutics, Inc. (Nasdaq: PSTX) develops allogeneic cell therapies and genetic medicines targeting cancer and rare genetic diseases using proprietary non-viral genetic engineering platforms including the piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system, Booster Molecule technology and nanoparticle delivery; its pipeline features CAR-T candidates such as P-BCMA-ALLO1 in Phase 1 for relapsed/refractory multiple myeloma with Regenerative Medicine Advanced Therapy and Orphan Drug designations, P-CD19CD20-ALLO1 in Phase 1 for B-cell malignancies and autoimmune diseases including recent IND filings for multiple sclerosis and systemic lupus erythematosus, P-MUC1C-ALLO1 in Phase 1 for solid tumors including breast, colorectal, lung, ovarian, pancreatic and renal cancers, P-BCMACD19-ALLO1 and P-CD70-ALLO1 in preclinical development for hematologic malignancies, alongside in vivo gene therapies like P-FVIII-101, P-OTC-101 and P-PAH-101 for hemophilia A, ornithine transcarbamylase deficiency and phenylketonuria respectively; the company operates GMP manufacturing facilities and targets patients with high unmet needs in oncology, immunology, neurology and rare diseases primarily in the United States. Founded in 2014 and headquartered in San Diego, California, Poseida maintains strategic collaborations with Roche initiated in 2022 for off-the-shelf CAR-T therapies in hematological malignancies and with Astellas for research funding. In November 2024, Poseida entered a definitive agreement to be acquired by Roche for $1.0 billion upfront plus up to $0.5 billion in contingent value rights tied to clinical and commercial milestones, with the transaction completing in Q1 2025 and integrating Poseida as a member of the Roche Group to accelerate allogeneic cell therapy development.
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Roche set to finalise $1.5bn Poseida Therapeutics takeover
Roche to complete acquisition of U.S. biopharma company Poseida
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
Poseida shares triple on Tuesday, boosted by Roche collaboration
Why This Gene-Therapy Company's Stock Is Rising 228%
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Roche to acquire US-based Poseida Therapeutics
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know